Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | ERBB3 over exp PIK3CA H1047R |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| ERBB3 over exp PIK3CA H1047R | breast cancer | resistant | Buparlisib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a breast cancer cell line xenograft model harboring ERBB3 (HER3) over expression and PIK3CA H1047R in brain metastases demonstrated resistance to treatment with Buparlisib (BKM120) (PMID: 28539475). | 28539475 | |
| ERBB3 over exp PIK3CA H1047R | breast cancer | sensitive | Buparlisib + Elgemtumab | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a breast cancer cell line xenograft model harboring ERBB3 (HER3) over expression and PIK3CA H1047R in brain metastases was sensitive to the combined treatment of Buparlisib (BKM120) and LJM716, demonstrating delayed tumor growth and better survival when compared to either treatment alone (PMID: 28539475). | 28539475 | |
| ERBB3 over exp PIK3CA H1047R | breast cancer | sensitive | Buparlisib + Pertuzumab | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a breast cancer cell line xenograft model harboring ERBB3 (HER3) over expression and PIK3CA H1047R in brain metastases was sensitive to the combined treatment of Buparlisib (BKM120) and Perjeta (pertuzumab), demonstrating delayed tumor growth and better survival when compared to either treatment alone (PMID: 28539475). | 28539475 |